Viking Therapeutics’ year-to-date stock performance.
Cava’s year-to-date stock performance.
Cava: “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
Rubrik’s year-to-date stock performance.
Rubrik: “It’s a good company, but the problem is, again, this market hates enterprise software.”
Forward Air’s year-to-date stock performance.
Forward Air: “There’s great consolidation happening in this industry.”
Bristol Myers Squibb’s year-to-date stock performance.
Bristol Myers Squibb: “Bristol-Meyers has a good dividend, and it’s going to take a long time for it to be able to come to fruition, all the things that they want to do. I think it is bottoming…But that doesn’t necessarily make us all that excited.”
Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
Disclaimer The CNBC Investing Club Charitable Trust holds shares of Eli Lilly.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? [email protected]
Brendan Martin is a tech enthusiast with a deep understanding of the latest technological innovations. He explores the intersection of science and technology, providing readers with insights into the digital revolution. When not immersed in the world of gadgets and code, Brendan enjoys experimenting with DIY tech projects.
